How recombinant AAV vectors are designed, assembled, purified, and characterized for reliable gene transfer

Adeno-associated virus, or AAV, is one of the most widely used viral vector platforms for gene delivery, gene therapy research, gene editing support, and disease modeling. In recombinant AAV systems, the native viral genome is replaced with a designed expression cassette, while the viral components required for replication and capsid assembly are supplied separately during production. This allows researchers to generate AAV vectors that can deliver a selected genetic payload without retaining the full wild-type viral genome.

AAV packaging is the process of producing recombinant AAV particles that contain the intended vector genome. It is a critical part of AAV vector generation because packaging quality directly affects vector titer, purity, genome integrity, empty/full capsid ratio, transduction performance, and experimental reproducibility. For both research and translational applications, careful design and characterization of packaged AAV vectors are essential.

What AAV Packaging Involves

Recombinant AAV packaging relies on coordinated delivery of three major functional components. The first is the transfer vector, which contains the gene of interest or functional expression cassette flanked by AAV inverted terminal repeats, or ITRs. The ITRs are the key cis-acting elements required for vector genome replication and packaging. The second component provides AAV Rep and Cap functions. Rep proteins support genome replication and packaging, while Cap proteins form the viral capsid and determine many aspects of tissue tropism and cell entry. The third component provides helper-virus functions, commonly derived from adenovirus helper genes, that support efficient AAV production in packaging cells.

In commonly used HEK293-based systems, these components are supplied through plasmids or related production formats. The packaged product is then harvested, purified, formulated, and tested to confirm that it meets the intended quality requirements. AAV packaging service platforms may vary in plasmid configuration, production scale, purification method, serotype selection, and analytical testing package.

Key Design Considerations Before Packaging

Successful AAV packaging begins with thoughtful vector design. The expression cassette must fit within AAV’s packaging capacity, generally around 4.7 kb for single-stranded AAV. Oversized genomes can reduce packaging efficiency and increase the risk of truncated or heterogeneous packaged genomes. For self-complementary AAV, the usable payload capacity is even smaller, typically around half of the standard AAV capacity.

Important design factors include:

• Serotype or capsid selection: The capsid affects tissue tropism, cell entry, biodistribution, immune recognition, and manufacturability.
• Promoter choice: Promoters can be constitutive, tissue-specific, cell-type-specific, inducible, or synthetic, depending on the desired expression profile.
• Expression cassette size: The transgene, promoter, regulatory elements, and polyadenylation signal must be compatible with AAV packaging limits.
• ITR integrity: ITRs are essential for AAV genome replication and packaging and should be carefully maintained during plasmid construction.
• Regulatory elements: Elements such as WPRE variants, introns, untranslated regions, and polyadenylation signals can influence expression strength, safety, and genome size.
• Application and delivery route: In vitro studies, local injection, systemic delivery, CNS delivery, ocular delivery, and liver-directed applications may require different capsids, titers, and quality attributes.

From Vector Assembly to AAV Production

After the vector design is confirmed, AAV packaging proceeds through production in a suitable host cell system. HEK293-derived cells are widely used because they support efficient AAV production and are compatible with transient transfection systems. Other platforms, including stable producer cell lines and baculovirus/Sf9 systems, may also be used depending on scale, application, and manufacturing strategy.

During production, the vector genome is replicated and packaged into newly assembled AAV capsids. The efficiency of this process depends on several factors, including plasmid design, Rep/Cap expression, helper gene activity, cell culture conditions, capsid serotype, transgene cassette, and harvest timing. Poorly optimized production can lead to low yield, high empty capsid content, residual impurities, or inconsistent batch performance.

Purification and Formulation

After production, AAV vectors must be recovered and purified from cells and/or culture media. Purification removes host-cell proteins, host-cell DNA, residual plasmid DNA, empty capsids, aggregates, and other process-related impurities. Common purification approaches include affinity chromatography, ion-exchange chromatography, density-gradient ultracentrifugation, tangential flow filtration, and polishing steps selected based on the product grade and intended application.

Formulation is also important. Buffer composition, salt concentration, surfactants, stabilizers, storage temperature, and freeze-thaw handling can all influence vector stability. Proper formulation helps maintain vector activity, reduce aggregation, and support consistent performance during storage and use.

Quality Control and Characterization

Quality control is essential for confirming that the packaged AAV vector is suitable for downstream experiments or development use. Depending on the application, testing may include vector genome titer, capsid titer, purity, residual host-cell DNA, residual plasmid DNA, endotoxin, mycoplasma, bioburden, empty/full capsid ratio, genome integrity, and functional transduction activity.

Common AAV quality attributes include:

• Vector genome titer.
• Capsid titer.
• Purity and protein profile.
• Empty/full capsid ratio.
• Residual host-cell DNA and plasmid DNA.
• Endotoxin and sterility-related attributes.
• Genome integrity and identity.
• Aggregation or particle distribution.
• Functional transduction or potency-related readouts.

Because no single assay fully defines AAV quality, robust characterization often relies on multiple complementary analytical methods. This is especially important for preclinical, IND-enabling, and GMP-oriented programs.

Why AAV Packaging Matters for Gene Therapy and Gene Editing Research

AAV packaging is a foundational step for many gene delivery applications. For gene therapy research, packaged AAV vectors can deliver therapeutic genes, reporters, gene silencers, or regulatory elements to target cells and tissues. For gene editing studies, AAV vectors can deliver guide RNAs, donor templates, compact editing components, or supporting payloads depending on the system design.

High-quality AAV packaging improves the likelihood that experimental results reflect the intended biology rather than variability in vector preparation. Consistent titer, purity, genome integrity, and transduction activity are essential for dose-response studies, animal experiments, disease modeling, and translational development.

Conclusion

AAV packaging is a critical step in converting vector design into a functional gene delivery tool. It requires coordinated control of vector genome design, capsid selection, production system, purification strategy, formulation, and analytical testing. When performed and characterized properly, AAV packaging provides researchers with reliable vectors for gene delivery, gene editing support, disease modeling, and gene therapy development.

As AAV technologies continue to evolve, advances in capsid engineering, plasmid architecture, stable production systems, purification, and analytical testing will further improve packaging efficiency, vector quality, and scalability.

How PackGene Supports Custom AAV Packaging

PackGene provides custom AAV packaging services to support research, preclinical, and translational gene therapy programs. Its AAV packaging platform offers fast turnaround, broad serotype selection, high-purity vector preparation, low endotoxin, low empty capsids, and customizable production options. PackGene’s public service information describes AAV packaging in as little as 12 business days, support for more than 70 serotypes, endotoxin levels below 10 EU/mL, and consistently low empty capsid levels for research applications.

PackGene also provides integrated AAV analytical testing services covering titer, purity, safety-related attributes, residual host-cell DNA, residual plasmid DNA, and other project-specific assays. By combining vector design support, scalable AAV packaging, purification, and quality-focused characterization, PackGene helps researchers move from construct design to high-quality AAV vectors for discovery, preclinical research, and gene therapy development.